31 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
10206553	55	Combined NK1 and NK2 tachykinin receptor antagonists: synthesis and structure-activity relationships of novel oxazolidine analogues.	Sankyo
7678430	23	Cyclic peptides as selective tachykinin antagonists.	Merck Sharp and Dohme Research Laboratories
	6	Peptide azoles: A new class of biologically-active dipeptide mmetics.	TBA
9703462	98	2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models.	Novartis Institute For Medical Sciences
7518002	38	Studies on neurokinin antagonists. 4. Synthesis and structure-activity relationships of novel dipeptide substance P antagonists: N2-[(4R)-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-prolyl]-N- methyl-N-(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and its related compounds.	Fujisawa Pharmaceutical
7693945	6	Synthesis, in vitro binding profile, and autoradiographic analysis of [3H]-cis-3-[(2-methoxybenzyl)amino]-2-phenylpiperidine, a highly potent and selective nonpeptide substance P receptor antagonist radioligand.	Pfizer
1331460	54	Conformationally constrained tachykinin analogues: potent and highly selective neurokinin NK-2 receptor agonists.	Glaxo Group Research
1375965	47	Studies on neurokinin antagonists. 1. The design of novel tripeptides possessing the glutaminyl-D-tryptophylphenylalanine sequence as substance P antagonists.	Fujisawa Pharmaceutical
12127519	40	Identification of a novel 1'-[5-((3,5-dichlorobenzoyl)methylamino)-3-(3,4-dichlorophenyl)-4-(methoxyimino)pentyl]-2-oxo-(1,4'-bipiperidine) as a dual NK(1)/NK(2) antagonist.	The Schering Plough Research Institute
11266174	51	Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold.	Novartis Institute For Medical Sciences
9873386	15	Synthesis and NK1 receptor antagonistic activity of (+/-)-1-acyl-3-(3,4- dichlorophenyl)-3-[2-(spiro-substituted piperidin-1'-yl)ethyl]piperidines.	Yamanouchi Pharmaceutical
	52	Synthesis and sar of 4-(1H-benzimidazole-2-carbonyl)piperidines with dual histamine H1/tachykinin NK1 receptor antagonist activity	TBA
	31	An SAR study for the non-peptide substance P receptor (NK1) antagonist, CP-96,345.	TBA
	76	Use of CoMFA in validating the conformation used in designing 4-(1H-benzimidazole-2-carbonyl)piperidines with H1/NK1 receptor antagonist activity	TBA
	42	Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists	TBA
	4	Perhydrothiopyranopyrroles derivatives : A novel series of potent and selective nonpeptide NK1 antagonists.	TBA
	13	Alternative strategies towards the identification of chemical lead compounds by rational design	TBA
	23	Methionine replacements in biologically active peptides	TBA
10937720	24	Combined tachykinin receptor antagonist: synthesis and stereochemical structure-activity relationships of novel morpholine analogues.	Sankyo
8759639	33	Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P.	Hebrew University of Jerusalem
8576917	79	3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.	Eli Lilly
7689652	6	Studies on neurokinin antagonists. 3. Design and structure-activity relationships of new branched tripeptides N alpha-(substituted L-aspartyl, L-ornithyl, or L-lysyl)-N-methyl-N-(phenylmethyl)-L-phenylalaninamides as substance P antagonists.	Fujisawa Pharmaceutical
7562907	33	New spiropiperidines as potent and selective non-peptide tachykinin NK2 receptor antagonists.	Glaxo Wellcome Medicines Research Centre
2433445	4	[pGlu6,Pro9]SP6-11, a selective agonist for the substance P P-receptor subtype.	TBA
1714957	12	Pseudopeptide analogues of substance P and leucine enkephalinamide containing the psi (CH2O) modification: synthesis and biological activity.	Hebrew University of Jerusalem
1694545	28	Potent and highly selective neurokinin antagonists.	Glaxo Group Research